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Abstract
Background: Despite the finding that Parkinson disease (PD) occurs in more than one in every
1000 people older than 60 years, there have been few attempts to quantify how deficits in
impairments, activity, participation, and quality of life progress in this debilitating condition. It is
unclear which tools are most appropriate for measuring change over time in PD.
Methods and design: This protocol describes a prospective analysis of changes in impairments,
activity, participation, and quality of life over a 12 month period together with an economic analysis
of costs associated with PD. One-hundred participants will be included, provided they have
idiopathic PD rated I-IV on the modified Hoehn & Yahr (1967) scale and fulfil the inclusion criteria.
The study aims to determine which clinical and economic measures best quantify the natural history
and progression of PD in a sample of people receiving services from the Victorian Comprehensive
Parkinson's Program, Australia. When the data become available, the results will be expressed as
baseline scores and changes over 3 months and 12 months for impairment, activity, participation,
and quality of life together with a cost analysis.
Discussion: This study has the potential to identify baseline characteristics of PD for different
Hoehn & Yahr stages, to determine the influence of disease duration on performance, and to
calculate the costs associated with idiopathic PD. Valid clinical and economic measures for
quantifying the natural history and progression of PD will also be identified.
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Background
Despite Parkinson disease (PD) affecting more than 4 mil-
lion people world wide [1], little is known about the rate
of disease progression, the costs of medical and allied
health management, or which measures best quantify
change over an episode of care. This trial protocol presents
the methods that will be used to map disease progression
in PD, as well as to identify valid clinical and economic
measures for quantifying the natural history and progres-
sion of this debilitating condition.
Parkinson's disease is a chronic and progressive condition
that is usually diagnosed in adults over the age of 60 years.
The incidence of PD is estimated to increase from 1.4 per-
cent of those aged 65–75 years to 4.3 percent of people
aged over 85 years [2,3]. The rapidly ageing population
throughout developed countries means that the number
of people with diagnosed PD will quickly increase over
the next 20 years. In addition to the impairments, activity
limitations and participation restrictions that accompany
PD, older adults may experience a range of age-related co-
morbidities. Therefore, elderly people with PD can be very
prone to complications such as falls, pneumonia and psy-
chosis which can add substantially to the already high
social and economic burden of the disease.
A recent literature review of cost of illness studies in
Europe relating to PD reported that the annualized direct
costs per patient ranged from €5,000 to €10,000 in 2002
[4]. Significant contributors to direct health system costs
include medication and medical and allied health services
[5-8], with a recent Australian prospective cohort study
finding that pharmaceutical expenses contributed approx-
imately 35% of total health care costs [5]. Individuals and
their carers also face significant home care costs, and pro-
ductivity losses [8]. Whilst cost of illness studies indicate
disease burden at a population level, this information is
only relevant where alternative treatment pathways exist,
and comparison then undertaken using cost effectiveness
methodologies.
Parkinson disease affects the basal ganglia deep within the
brain, leading to a reduction in the size and speed of
sequential movements, particularly for motor skills [9].
These activities are normally performed automatically,
such as walking, balance, postural control, bed mobility,
manipulative tasks, speech, conversation and swallowing
[10,11]. The basal ganglia also automate cognitive events,
mood and behaviour [12]. Dysfunction in these domains
can result in difficulty with driving, shopping, attending
to financial matters, conversations, mood and relation-
ships [13]. The disease can eventually involve other brain
areas which control bowel, bladder, blood pressure, sleep,
mood and cognition. Although no cure exists, treatment is
available for the symptoms of PD, particularly for move-
ment disorders.
Medication compensates for the reduced levels of
dopamine in the brain and increases the size and speed of
automatic movements [14]. Unfortunately because of the
progression of the disease, benefits diminish and
unwanted movements develop which can further impair
activity, participation, and well-being [14,15]. Typically
this takes place around 3–5 years after medication is com-
menced. People can then experience fluctuations in
mobility, often unpredictably, making life very difficult
and requiring more assistance. For these reasons, some cli-
nicians advocate an inter-professional team approach to
the management of the complex array of disorders of
movement, cognition and autonomic function [16-19].
Because PD is progressive, management incorporates eval-
uation of the rate of progression of impairments, activity
limitations and participation restrictions [20]. Treatment
aims to limit the rate and level of progression to enable
people with PD and others in their lives to enjoy the high-
est possible quality of life [21].
The study will be conducted in Melbourne Australia, the
home of the Victorian Comprehensive Parkinson Pro-
gram (VCPP). The VCPP incorporates several large inter-
professional teams, a specialist knowledge base, health
professional training in best practice, and long term expe-
rience in management of problems experienced by those
with PD. The specialist knowledge base includes pharma-
cological knowledge and the patho-physiology of PD
symptoms, manifestations and management. It also
includes a specific, evidence-based rehabilitation program
which aims to enable people with PD to perform normal
movements when these are not possible in the setting of
medication failure or ineffectiveness. This rehabilitation
program is shared by all disciplines and acts as a common
language for the patients irrespective of the team member.
The program has a proactive approach to management,
identifying problems early and instituting appropriate
management. All contact points are managed by expert
multi-disciplinary teams. People with PD are empowered
to make decisions about their own health care and to be
actively involved in management under supervision of rel-
evant team members.
The VCPP is an example of one model of care that
embraces this philosophy by providing high quality inpa-
tient, outpatient and home-based services from a special-
ist inter-professional team of clinicians and clinical
researchers. It provides services for more than 1500
patients within a 30 km radius and has 2–4 new referrals
per week, providing a unique opportunity for clinical
research. The team includes neurologists, physical thera-
pists, occupational therapists, speech pathologists, socialBMC Geriatrics 2009, 9:2 http://www.biomedcentral.com/1471-2318/9/2
Page 3 of 6
(page number not for citation purposes)
workers, psychologists, nurses, dieticians and general
medical practitioners. Before service provision models
such as this can be comprehensively evaluated, there is a
need for preliminary investigations to determine the best
measurement tools to quantify therapy outcomes and
program costs. Further data are also needed to map dis-
ease progression in a sample of people with PD from this
service, providing a frame of reference against which inter-
disciplinary therapy outcomes can later be evaluated. The
study protocol presented in this paper aims to address
these needs as the first step in measuring the outcomes
and costs of an inter-professional team model for the
comprehensive management of people with PD.
Thus the key aims of this initial "proof of concept" inves-
tigation are to:
(i) Determine which tests and measurement procedures
best capture the multi-dimensional and progressive
nature of PD, including clinical effectiveness measures
and cost related measures;
(ii) Use this robust test battery that is sensitive to the man-
ifestations of PD to quantify the outcomes of disease pro-
gression over a sample period of 12 months in a large
sample of people from the VCPP;
(iii) Quantify resource use and costs associated with the
management of PD from health system and societal per-
spectives; and
(iv) Develop a regression model to predict the statistical
importance of clinical outcome and quality of life (QoL)
measures on cost and health care utilization over a 12-
month period.
The key research questions are:
(i) What is the natural history of disease progression in
the impairment, activity, participation, well-being, and
quality of life domains over a 12 month period in a sam-
ple of people receiving inter-disciplinary services from the
VCPP?
a. Which field-tested protocols and outcome measures
best quantify disease progression for use in future clin-
ical trials of new and/or current interventions for the
management of PD?
b. How does quality of life for people with PD change
with disease progression?
c. How does caregiver strain change with disease pro-
gression?
(ii) What are the costs of care (including informal care,
services utilized and events attributable to PD by initial
disease state and progression from both a health system
and societal perspective) for people with PD receiving care
from VCPP?
This involves the establishment of a database to store large
volumes of costing and clinical data from multiple
sources, and the development of a model to predict the
statistical importance of clinical outcome and quality of
life measures on cost and health care utilization over a 12-
month period for the VCPP.
Methods and design
Study design
This is a prospective cohort study comprising primary and
secondary collection of clinical, health related quality of
life and cost data for people with PD.
Population
We plan to recruit 100 newly referred persons with PD
through the VCPP at participating centres in Melbourne,
Australia. Inclusion criteria are a confirmed diagnosis of
idiopathic PD, informed consent (including to access
Medicare Australia claims data), carer participation in case
of cognitive impairment (MMSE<24/30), and ability to
attend assessment clinics and to complete questionnaires
over a 12-month period. People will be excluded from the
study if they are Hoehn & Yahr Stage V, non-ambulatory,
or have co-existing neurological conditions which are
related to significant motor and cognitive function
impairment, are unwilling to provide informed consent,
or to participate in a clinical trial.
Sample size
Given that this is a prospective observational cohort study
without formal comparison groups, there is no issue of
statistical power to be considered. However, we need suf-
ficient numbers of participants to obtain useful estimates
of costs, health care utilization and outcome measures,
including quality of life. We propose to enrol a total of
100 eligible participants. The VCPP has an average of 2–4
new PD referrals per week (45 weeks of the year) and,
anticipating an approximate rate of 75% of patients con-
senting to participate, it will be feasible to enrol 100 eligi-
ble participants over a 16–24 month interval. It is
predicted there will be a 5% attrition rate during the 12
month data collection time period. Precision of estimates
derived from a cohort of n = 100 participants will be suf-
ficient for continuous variables (e.g. walking speed, mean
step length) confidence interval width will be about 0.14
times the PD population standard deviation (e.g. ± 1.7 m/
min for walking speed, ± 0.028 m for stride length); for
binary outcomes (e.g. falls) the resulting confidence inter-BMC Geriatrics 2009, 9:2 http://www.biomedcentral.com/1471-2318/9/2
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val width will be less than ± 7% if the underlying rate is
50% and ± 4% if the rate is less than 10%.
Sampling strategy
Recruitment will be approximately equal numbers across
four categories: (i) PD duration < 1 year; (ii) PD duration
1–5 years; (iii) PD duration 6–10 years; and (iv) PD dura-
tion greater than 10 years. The definitions of disease sever-
ity will be according to the modified Hoehn & Yahr [22]
stages.
Data collection procedures
After obtaining informed consent from people with PD
and their carers, we will record a range of baseline meas-
urements (see Table 1). Participants will be seen by a
trained therapist either in their own home, at the Kingston
clinic or at a local clinic. They will each be seen three times
(baseline, 3 months and 12 months) during the course of
their participation in the study. A project officer will also
contact each participant on ten occasions (month 1, 2, 4–
11) for completion of a monthly questionnaire of health-
related events.
Method for health-related costs and utilization data 
collection
People with PD will be asked to complete a monthly ques-
tionnaire of health-related events designed to record visits
to health care facilities, any out-of-pocket expenses
incurred, medications, and transport to health services
during the 12 month follow-up period (refer Table 2).
Physical therapist surveyors will be trained in the task of
reviewing data obtained from these questionnaires and
clarifying information when necessary at the 3-month and
12-month visits. A health economist will work through-
out the duration of the program to train, support and
oversee the surveyors in the collection of health-care
related information.
We will seek participants' permission to obtain details of
costs associated with visits to any Southern Health facility
during the course of the 12-month follow-up. We will also
seek permission to obtain Medicare Australia individual
claims data relating to medical visits, diagnostic tests and
other items included on the Commonwealth Medicare
Benefits Schedule. These data are indexed by a unique
identification number ("Medicare" number), which we
shall obtain for each participant. We shall obtain details
of all Medicare claims for the 12 months of active follow-
up and for the 12 months prior to enrolment in the
cohort.
Statistical analysis
The principal outcome event rates and changes in out-
come measures shall be estimated during the 12 month
follow-up interval. Generally, these will need only to be
measured as binary outcomes, rate estimates for event
data (e.g. falls) and sample means and standard devia-
tions. We shall compute appropriate confidence intervals
for outcome measures, changes in outcome measures, and
differences between cohort strata. We shall employ ran-
dom-effects cross-sectional time series models to estimate
differences between strata using repeated-measures out-
come data. Comprehensive patient level cost and health-
care utilization data can be estimated for each patient.
Additional resource use attributable to Parkinson related
events can also be determined. Regression analysis will
identify the main clinical and socioeconomic predictors
of cost and resource use over 12 months in a cohort of
people with PD receiving comprehensive care.
Ethics approval
Ethics approvals were obtained from the Southern Health
Human Research Ethics Committee (HREC Number
06107B) and Monash University Standing Committee on
Ethics in Research Involving Humans (SCERH No. 2006/
728MCC) of Australia.
Discussion
This trial shall provide a deeper understanding of disease
progression over a 12 month period in a large community
based sample of people with PD. It shall also generate
high quality cost measurements and comprehensive
Table 1: Clinical and health related quality of life measures at baseline, 3 and 12 months
Clinical Measures Baseline 3 months 12 months
UPDRS [26] XX X
Modified Dyskinesia Rating Scale [27] X X X
PDQ-39 [28] XX X
EUROQOL-5D XX X
10 m walking test [13] X X X
Timed Up & Go [29] X X X
Parkinson Disease Fatigue Scale (PDF16) X X X
Geriatric Depression Scale X X X
Neuro-psychiatric inventory of care giver burden X X
Motor fluctuation diary for previous 24–48 hours (if relevant) X X XBMC Geriatrics 2009, 9:2 http://www.biomedcentral.com/1471-2318/9/2
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health care utilization data for PD by disease stage. High
quality standard deviations for outcome and quality of
life and caregiver strain measures will be identified which
can be used later to plan intervention studies. An addi-
tional result will be a battery of clinical measurement
tools which have been field-tested and evaluated with
respect to known domains of disability and health, meas-
ured variance, precision and clinical utility.
Although there is no comparison intervention for a full
economic evaluation, the cost measurements could be
incorporated into future planned studies on the costs
effectiveness of interventions for PD, including compre-
hensive strategies such as the VCPP compared with rou-
tine care. Cost comparisons can be undertaken between
cohorts, where cohorts are determined by disease stage.
This analysis will be relevant to future research where
interventions are aimed at slowing disease progression.
The data will provide us with information required to
select suitable measurement tools so that we can compare
the effects of conventional care with a comprehensive
model of inter-professional practice. Inter-professional
coordinated care models for chronic diseases such as PD
are becoming more common with models of care recently
established in Europe [18,19,23-25] and North America
[17]. Collection of cost, clinical and health related quality
of life data in complex settings where a range of health
services are provided is a resource intensive exercise. By
identifying the tests that are most sensitive to the manifes-
tations of PD and the methods by which these data may
be collected is likely to reduce data issues associated with
complex interventions in the future. Particularly cost data
where a range of data sources from community-based pri-
mary health care, specialised multidisciplinary outpatient
teams to acute hospital settings are likely to be integrated
in a single intervention. Ultimately this will reduce the
burden of data collection in a trial context for both partic-
ipants and researchers.
The care giver strain questionnaire will provide detailed
information on the indirect costs and resource use associ-
ated with PD. These costs are not often included in eco-
nomic evaluations for chronic disease and use in future
research will enable cost effectiveness studies to take a
broader societal perspective as compared to a narrow
health system perspective. Knowledge of carer burden
may also enable more effective community support serv-
ices for PD directed to areas of need.
By identifying valid, discriminative and feasible tools to
quantify changes over 12 months in people with PD as
well as mapping typical progression over a 12 month
period, we shall be better placed to compare these com-
prehensive intervention strategies with routine care and
absence of intervention.
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Table 2: Economic data
Economic Data Baseline 12 months Monthly
Employment status (type, hours) X X
Income change ($) X X
Leisure activities (hours) X X
Government allowances X X
Informal care assistance (hours) X X
Formal carer (type, hours, cost) X X
Home Help (type, hours, cost) X X
Community-based services (type, cost) X X
Hospital admission (reason, transport mode, days) X
Primary health care services (type, frequency) X
Non-admitted patient services (type, frequency) X
Medication (name, dose, frequency) XPublish with BioMed Central    and   every 
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